US2014171621A1PendingUtilityA1

Galectin-Immunoglobulin Chimeric Molecules

39
Assignee: BRIGHAM & WOMENS HOSPITALPriority: Jun 23, 2009Filed: Dec 2, 2013Published: Jun 19, 2014
Est. expiryJun 23, 2029(~2.9 yrs left)· nominal 20-yr term from priority
Inventors:Charles J. DimitroffFiliberto Cedeno LaurentSteven R. Barthel
A61P 37/00C07K 16/00A61K 38/00A61P 37/06C07K 2319/30C07K 14/47A61P 35/00C07K 14/4726
39
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Described are Galectin-1/Ig fusion constructs and methods of use thereof, e.g., in diagnostic and biomedical assays, and as therapeutic agents for the treatment of conditions associated with immune dysfunction, e.g., autoimmune diseases, and cancers.

Claims

exact text as granted — not AI-modified
1 . An isolated Galactin-1-Ig (Gal-Ig) fusion construct, comprising:
 a first portion comprising a Galectin-1 polypeptide, and   a second portion comprising an Fc fragment of an immunoglobulin or a variant thereof, linked in frame with the first portion, optionally with a linker sequence between the first and second portions.   
     
     
         2 - 16 . (canceled)

Join the waitlist — get patent alerts

Track US2014171621A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.